Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative

Fig. 2

OS in patients diagnosed with stage IIIB–IV NSCLC in 2012–2016 by (a) stage, (b) histology, and (c) EGFR/ALK mutational/rearrangement status. OS curves for histology (panel b) shown for combined stage IIIB–IV population; OS curves for EGFR/ALK mutational/rearrangement status (panel c) shown for combined stage IIIB–IV population and only for patients with NSQ. OS overall survival, NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor gene, ALK anaplastic lymphoma kinase gene, CI confidence interval, IQR interquartile range, NSQ non-squamous cell carcinoma, SQ squamous cell carcinoma

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us